Pelage has dosed the first participant in AWAKEN, a 600-patient Phase 2/3 trial of topical PP405 for male pattern hair loss. The programme follows an exploratory Phase 2a finding in which 31% of selected treated men achieved more than 20% improvement in hair density, compared with none receiving placebo.
Auxilium Biotechnologies bioprints kidney and liver tissues in orbit, advancing microgravity biofabrication while major clinical hurdles remain.
Find out how Syntax Bio’s expanded Series A could shape Cellgorithm-based beta cell therapy for type 1 diabetes.
How NewcelX Ltd. is advancing NCEL-101 toward a functional diabetes cure through durable islet graft survival and immune protection strategies.
iPSC demand is rising fast. FUJIFILM’s Madison facility tests whether stem cell manufacturing can keep pace with pharma and cell therapy needs.
Beauty wants biotech credibility. AVL’s IVF-inspired skincare push tests whether longevity science can reshape premium skincare.
Cell therapy scale-up is not just a science problem. Charles River and MEDIPOST are targeting the GMP testing bottleneck.
MSC science is advancing faster than manufacturing can scale. Terumo BCT and Steminent are testing whether automation can close that gap.
Novo shelved the asset, but Cellular Intelligence sees a platform test. Parkinson’s cell therapy now faces its harder commercial trial.
ACL surgery needs better graft choices. CoreTissue BioEngineering’s CT-ACL001 now faces the harder randomized test.